SABS Historical PE Ratio image   This SABS PE ratio history page last updated 4/16/2024
SABS PE History Chart
PeriodPriceGAAPTTMPE
Q3 2023
11/13/2023
9.30-1.00-5.70NA
Q2 2023
8/21/2023
7.90-1.40-6.30NA
Q1 2023
5/16/2023
7.80-1.50-6.00NA
Q4 2022
4/14/2023
7.26-1.80-4.30NA
Q3 2022
11/15/2022
10.60-1.60-2.50NA
Q2 2022
8/10/2022
11.20-1.10NANA
Q1 2022
5/12/2022
17.900.20NANA
SABS Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q3 2023
11/13/2023
9.30-1.00-4.00NA
Q2 2023
8/21/2023
7.90-1.40-5.60NA
Q1 2023
5/16/2023
7.80-1.50-6.00NA
Q4 2022
4/14/2023
7.26-1.80-7.20NA
Q3 2022
11/15/2022
10.60-1.60-6.40NA
Q2 2022
8/10/2022
11.20-1.10-4.40NA
Q1 2022
5/12/2022
17.900.200.8022.4
Quotes delayed 20 minutes

Email EnvelopeFree SABS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
SAB Biotherapeutics (SABS) is categorized under the Miscellaneous sector; to help you further research PE history across stocks, below are some other companies in the same sector:

SBBP PE Ratio History
SCLX PE Ratio History
SES PE Ratio History
SHPW PE Ratio History
SKIL PE Ratio History
SLDP PE Ratio History
SLGC PE Ratio History
SMFR PE Ratio History
SMR PE Ratio History
SMRT PE Ratio History
On this page we presented the SABS PE Ratio History information for SAB Biotherapeutics' stock. The average SABS PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 22.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average SABS PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this SABS PE ratio history result, against the recent PE: when this page was posted on 4/15/2024, the most recent closing price for SABS had been 4.61, and the most recent quarterly earnings result, annualized, was 0.8. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent SABS PE on 4/15/2024 based on annualized quarterly EPS was 5.8. Based on SABS's history, that recent PE is low relative to the historical average, with the recent PE 74.1% lower than the historical average PE across our data set for SAB Biotherapeutics.

For self directed investors doing their due diligence on SABS or any other given stock, valuation analysis for SABS can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate SAB Biotherapeutics PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for SABS. Thanks for visiting, and the next time you need to research SABS PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: PLSE market cap history, Top Ten Hedge Funds Holding RELX, Funds Holding LYT.

 

SABS PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2024, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.7%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.7%.